References
- Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433–7
- NORM/NORM-VET. 2005.
- Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–3
- Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473–81
- Beyer D, Pepper K. The streptogramin antibiotics: updates on their mechanisms of action. Expert Opin Investig Drugs 1998; 7: 591–9
- Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43: 1062–6
- Kehoe LE, Snidwongse J, Courvalin P, Rafferty JB, Murray IA. Structural basis of synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. J Biol Chem 2003; 278: 29963–70
- Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semi-synthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992; 30(Suppl A)67–75
- Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132–6
- Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45: 2154–6
- Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207–8
- Andersen, BM, Dalen, HE, Steinbakk, M, Syversen, G, Bruun, JN, Magnaes, B, , et al. Methicillin resistant yellow staphylococci. Tidsskr Nor Laegeforen 1998;118:1182–5. (In Norwegian).
- Brakstad OG, Maeland JA, Tveten Y. Multiplex polymerase chain reaction for detection of genes for Staphylococcus aureus thermonuclease and methicillin resistance and correlation with oxacillin resistance. APMIS 1993; 101: 681–8
- National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing-Twelfth Informational Supplement. NCCLS document M100-S12 (ISBN 1-56238-454-6). NCCLS, Wayne, PAUSA.
- E-test application sheet-EAS008, AB Biodisk, Solna, Sweden.
- Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000; 46: 931–40
- Ballow CH, Jones RN, Biedenbach DJ. A multicentre evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43: 75–83
- Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 2002; 8: 791–800
- Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn Microbiol Infect Dis 2002; 43: 65–73
- Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. International Journal of Antimicrobial Agents 2006; 28: 385–8
- Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrobial Agents Chemother 2006; 50: 2680–5
- Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centres (2003). Diagnostic Microbiology & Infectious Disease 2005; 53: 329–32
- Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. International Journal of Antimicrobial Agents 2004; 24: 59–66
- Richter SS, Kealey DE, Murray CT, Heilmann KP, Coffman SL, Doern GV. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. Journal of Antimicrobial Chemotherapy 2003; 52: 123–7